

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/Caplus
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and LMEDLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12 APR 26 PROMT: New display field available
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 14 APR 26 LITALERT now available on STN
NEWS 15 APR 27 NLDB: New search and display fields available
NEWS 16 May 10 PROUSDDR now available on STN
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May
and June 2004
NEWS 18 May 12 EXTEND option available in structure searching
NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20 May 17 FRFULL now available on STN

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:35:20 ON 18 MAY 2004

MISSING OPERATOR

=> help

The arrow (=>) is the system prompt, where you enter a command. For an explanation of system commands, files, formats, etc., enter "HELP" and the name of the item you want explained at an arrow prompt (=>). Enter "HELP COMMANDS" for a list of commands that can be used in this file. Enter "HELP MESSAGES" for a list of online explanations that are available. The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message. Enter "HELP" or "?" at a prompt to see an explanation of the options. After an error message, enter "HELP" or "?" at the next prompt and you will receive a more detailed explanation of the error and how to correct it.

Automatic help is also available. When AUHELP is 'ON', you will automatically receive help following an error message. For more information on AUHELP, enter "HELP SET AUHELP" at an arrow prompt (=>).

Users who need additional assistance can contact the Help Desk at their nearest STN Service Center. Enter "HELP STN" for information on STN Service Centers. You may also choose to contact the database representative for the file you are searching, for more detailed help on database content and search strategy. For information on how to contact database representatives for the current file, enter "HELP DESK" at an arrow prompt (=>).

=> help messages

Many HELP messages are available to explain files and features of the system. Each command has a separate explanation that can be viewed by entering HELP (or ?) followed by the command name at an arrow prompt (=>). Enter HELP COMMANDS for a list of commands.

Example: => HELP PRINT

Some commands have detailed help for specific functions for that command. At an arrow prompt, enter HELP followed by the command name and the specific option:

HELP DISPLAY (ACC, BROWSE, COST, EXPAND, FORMAT, HISTORY, L#, PRINT, QUERY, SAVED, SCAN, SELECT, SET, TOLERANCE, TSORT, UNIT)

HELP PRINT (ACC, L#, TSORT)

HELP READ (FOLDER, MAIL, NAMELIST, PUBLIC)

HELP SEARCH (PROJECTIONS, RANGE, STEPS, SUBSET)

HELP SET (ABBREVIATION, ACCOUNT, AUHELP, AUTOSEARCH, BANNER, CLUSTER, COST, DCLUSTER, DETAIL, DFORMAT, DUPORDER, EXPAND, FAX, FAXC, FAXN, FIELD, FORMAT, GRAPHICS, HEADING, HIGHLIGHTING, INTERPRET, KWIC, LCOST, LINELENGTH, LOGIN, MAILID, NAMELIST, NOTICE, PADDING, PAGELength, PASSWORD, PATENT, PERMANENT, PLURALS, POSTINGS, PRINT, PROXIMITY, RANGE, RELATION, ROLES, ROUND, SELORDER, SFIELDS, SMARTSELECT, STATUS, STEPS, SUBSET, TERM, TLANGUAGE, TOLERANCE, UNIT)

The logical search operators have HELP messages to explain their functions. At an arrow prompt, enter HELP followed by the operator:

HELP AND

HELP OR

HELP NOT

HELP (W)

HELP (A)
HELP (L)
HELP (P)
HELP (S)
HELP (NOTPROXIMITY)

HELP NUMERIC

For more information on the available operators, enter HELP OPERATORS at an arrow prompt.

Each file has its own set of HELP messages. For a list of files, enter HELP FILE NAMES. For information about helps available for the current file, enter HELP DIRECTORY.

Messages that are available on other topics:

HELP COMMAND STACKING
HELP FILE COST
HELP LIMITS
HELP MAIL
HELP PACKAGES
HELP RESERVED
HELP SAVED NAMES
HELP TRUNCATION

=> s l2 and ((cavity form?) or (NaK ATPase) or (BDNF/Nt3 heterodimer) or (NGF dimer) or (IL 1) or (FGFB) or (IL 1b) or (IL 2) or (IL 3) or interleukin# or (GM csf) or EGF or FGF or barnase or (T4 lysozyme) or (TGF beta) or IgG)
MISSING OPERATOR

=> d his

(FILE 'HOME' ENTERED AT 15:35:20 ON 18 MAY 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 15:35:47 ON 18 MAY 2004

L1 61086 S (DRUG DELIVERY) AND (TARGET? OR ANTIBOD? OR COMPLEX?)
L2 32431 S L1 AND (PROTEIN OR (CELL SURFACE PROTEIN) OR RECEPTOR OR (CEL

=> s l2 and ((cavity form?) or (NaK ATPase) or (BDNF Nt3 heterodimer) or (NGF dimer) or (IL 1) or (FGFB) or (IL 1b) or (IL 2) or (IL 3) or interleukin# or (GM csf) or EGF or FGF or barnase or (T4 lysozyme) or (TGF beta) or IgG)

3 FILES SEARCHED...

4 FILES SEARCHED...

L3 13206 L2 AND ((CAVITY FORM?) OR (NAK ATPASE) OR (BDNF NT3 HETERODIMER)
) OR (NGF DIMER) OR (IL 1) OR (FGFB) OR (IL 1B) OR (IL 2) OR
(IL 3) OR INTERLEUKIN# OR (GM CSF) OR EGF OR FGF OR BARNASE OR
(T4 LYSOZYME) OR (TGF BETA) OR IGG)

=> s l3 and (non covalent?)

L4 3993 L3 AND (NON COVALENT?)

=> s l4 and (carrier# or excipient#)

L5 3864 L4 AND (CARRIER# OR EXCIPIENT#)

=> s l5 and (ions or radioisotopes or (cytotoxic?) or antiviral? or antibiotic# or prodrug#)

L6 3665 L5 AND (IONS OR RADIOISOTOPES OR (CYTOXIC?) OR ANTIVIRAL? OR
ANTIBIOTIC# OR PRODRUG#)

=> s l6 and (target or molecule or cell or tissue or organ or virus or bacteria or yeast or fungus)

6 FILES SEARCHED...

L7 3665 L6 AND (TARGET OR MOLECULE OR CELL OR TISSUE OR ORGAN OR VIRUS
OR BACTERIA OR YEAST OR FUNGUS)

=> S L7 AND (antibod? or (non peptid?) or lectin or polysaccharide or heparin)

L8 3656 L7 AND (ANTIBOD? OR (NON PEPTID?) OR LECTIN OR POLYSACCHARIDE
OR HEPARIN)

=> s l8 and ((fusion protein) or (target binding protein))

UNMATCHED LEFT PARENTHESIS 'AND ((FUSION'

The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l8 and ((fusion protein) or (target binding protein))

L9 3069 L8 AND ((FUSION PROTEIN) OR (TARGET BINDING PROTEIN))

=> s l9 and (pharmaceutic? or drug or bioactive or active or bioeffect? or
therapeutic?)

L10 3069 L9 AND (PHARMACEUTIC? OR DRUG OR BIOACTIVE OR ACTIVE OR BIOEFFE
CT? OR THERAPEUTIC?)

=> d his

(FILE 'HOME' ENTERED AT 15:35:20 ON 18 MAY 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 15:35:47 ON 18 MAY 2004

L1 61086 S (DRUG DELIVERY) AND (TARGET? OR ANTIBOD? OR COMPLEX?)
L2 32431 S L1 AND (PROTEIN OR (CELL SURFACE PROTEIN) OR RECEPTOR OR (CEL
L3 13206 S L2 AND ((CAVITY FORM?) OR (NAK ATPASE) OR (BDNF NT3 HETERODI
L4 3993 S L3 AND (NON COVALENT?)
L5 3864 S L4 AND (CARRIER# OR EXCIPIENT#)
L6 3665 S L5 AND (IONS OR RADIOISOTOPES OR (CYTOXIC?) OR ANTIVIRAL? OR
L7 3665 S L6 AND (TARGET OR MOLECULE OR CELL OR TISSUE OR ORGAN OR VIR
L8 3656 S L7 AND (ANTIBOD? OR (NON PEPTID?) OR LECTIN OR POLYSACCHARID
L9 3069 S L8 AND ((FUSION PROTEIN) OR (TARGET BINDING PROTEIN))
L10 3069 S L9 AND (PHARMACEUTIC? OR DRUG OR BIOACTIVE OR ACTIVE OR BIOE

=> s l4 and interior and (nonpolar cavity)

L11 2 L4 AND INTERIOR AND (NONPOLAR CAVITY)

=> s l10 and interior and (nonpolar cavity)

L12 2 L10 AND INTERIOR AND (NONPOLAR CAVITY)

=> d l12 1-2 ibib abs

L12 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2002:143956 USPATFULL

TITLE: **Protein** occlusion for delivery of small
molecules

INVENTOR(S): Panayotatos, Nikos, 95 Monmouth Ct., Orangeburg, NY,
United States 10962-2711

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406710	B1	20020618
	WO 9726275		19970724
APPLICATION INFO.:	US 1998-101860		19980716 (9)
	WO 1997-US675		19970116
			19980716 PCT 371 date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Fish & Neave, Haley, Jr., James F., Rochester, S. Craig		
NUMBER OF CLAIMS:	20		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to **complexes** between (1) a **target-binding moiety**; (2) a **cavity-forming moiety**; and (3) a pharmacological compound to be delivered to a **target**, wherein the pharmacological compound is buried inside of the **cavity-forming moiety**, but not covalently bound to either the **target-binding moiety** or the **cavity-forming moiety**. The **complexes** of this invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the **target-binding moiety** portion of the **complex**. The present invention also relates to **pharmaceutical** compositions comprising the **non-covalent complexes** of this invention. The invention also relates to methods of delivering a pharmacological compound to a **target** in a patient. The present invention also relates to the use of the **complexes** of this invention for the separation of chemical entities from their chiral forms or contaminants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2002:8064 USPATFULL
TITLE: Use of **protein** occlusion for the selective delivery of small molecules to **targets**
INVENTOR(S): Panayotatos, Nikos, Orangeburg, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004061	A1	20020110
APPLICATION INFO.:	US 2001-942463	A1	20010829 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-101860, filed on 16 Jul 1998, PENDING A 371 of International Ser. No. WO 1997-US675, filed on 16 Jan 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9804P	19960116 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	889	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to **complexes** between (1) a **target-binding moiety**; (2) a **cavity-forming moiety**; and (3) a pharmacological compound to be delivered to a **target**, wherein the pharmacological compound is buried inside of the **cavity-forming moiety**, but not covalently bound to either the **target-binding moiety** or the **cavity-forming moiety**. The **complexes** of this invention may be used as to deliver a pharmacological compound to cells, tissues, organs, viruses, microorganisms or other surfaces that are characterized by an entity that binds the **target-binding moiety** portion of the **complex**. The present invention also relates to **pharmaceutical** compositions comprising the **non-covalent complexes** of this invention. The invention also relates to methods of delivering a pharmacological compound to a **target** in a patient. The present invention also relates to the

use of the **complexes** of this invention for the separation of chemical entities from their chiral forms or contaminants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:35:20 ON 18 MAY 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 15:35:47 ON 18 MAY 2004

L1 61086 S (DRUG DELIVERY) AND (TARGET? OR ANTIBOD? OR COMPLEX?)
L2 32431 S L1 AND (PROTEIN OR (CELL SURFACE PROTEIN) OR RECEPTOR OR (CEL
L3 13206 S L2 AND ((CAVITY FORM?) OR (NAK ATPASE) OR (BDNF NT3 HETERODI
L4 3993 S L3 AND (NON COVALENT?)
L5 3864 S L4 AND (CARRIER# OR EXCIPIENT#)
L6 3665 S L5 AND (IONS OR RADIOISOTOPES OR (CYTOXIC?) OR ANTIVIRAL? OR
L7 3665 S L6 AND (TARGET OR MOLECULE OR CELL OR TISSUE OR ORGAN OR VIR
L8 3656 S L7 AND (ANTIBOD? OR (NON PEPTID?) OR LECTIN OR POLYSACCHARID
L9 3069 S L8 AND ((FUSION PROTEIN) OR (TARGET BINDING PROTEIN))
L10 3069 S L9 AND (PHARMACEUTIC? OR DRUG OR BIOACTIVE OR ACTIVE OR BIOE
L11 2 S L4 AND INTERIOR AND (NONPOLAR CAVITY)
L12 2 S L10 AND INTERIOR AND (NONPOLAR CAVITY)

=> d l10 and (disassociation constant)

'AND' IS NOT A VALID FORMAT

'(DISASSOCIATION' IS NOT A VALID FORMAT

'CONSTANT)' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):..

L10 ANSWER 1 OF 3069 USPATFULL on STN

AN 2004:120562 USPATFULL

TI Secreted and transmembrane polypeptides and nucleic acids encoding the same

IN Baker, Kevin P., Darnestown, MD, UNITED STATES
Botstein, David, Belmont, CA, UNITED STATES
Eaton, Dan L., San Rafael, CA, UNITED STATES
Ferrara, Napoleone, San Francisco, CA, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Gerritsen, Mary E., San Mateo, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Godowski, Paul J., Burlingame, CA, UNITED STATES
Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
Kljavin, Ivar J., Pacifica, CA, UNITED STATES
Napier, Mary A., Hillsborough, CA, UNITED STATES
Roy, Margaret Ann, San Francisco, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES

PA Genentech, Inc. (U.S. corporation)

PI US 2004091972 A1 20040513

AI US 2001-943664 A1 20010830 (9)

RLI Continuation of Ser. No. US 2001-866028, filed on 25 May 2001, PENDING
Continuation of Ser. No. US 1998-216021, filed on 16 Dec 1998, ABANDONED
Continuation of Ser. No. US 1998-218517, filed on 22 Dec 1998, ABANDONED
Continuation of Ser. No. US 1999-254311, filed on 3 Mar 1999, ABANDONED
A 371 of International Ser. No. WO 1998-US25108, filed on 1 Dec 1998, PENDING

PRAI	WO 1998-US19330	19980916
	WO 1998-US25108	19981201
	WO 1999-US12252	19990602
	WO 1999-US21090	19990915
	WO 1999-US28409	19991130
	WO 1999-US28313	19991130
	WO 1999-US28301	19991201
	WO 1999-US30095	19991216
	WO 2000-US3565	20000211
	WO 2000-US4414	20000222
	WO 2000-US5841	20000302
	WO 2000-US8439	20000330
	WO 2000-US14042	20000522
	WO 2000-US20710	20000728
	WO 2000-US32678	20001201
	WO 2001-US6520	20010228
	US 1997-67411P	19971203 (60)
	US 1997-69334P	19971211 (60)
	US 1997-69335P	19971211 (60)
	US 1997-69278P	19971211 (60)
	US 1997-69425P	19971212 (60)
	US 1997-69696P	19971216 (60)
	US 1997-69694P	19971216 (60)
	US 1997-69702P	19971216 (60)
	US 1997-69870P	19971217 (60)
	US 1997-69873P	19971217 (60)
	US 1997-68017P	19971218 (60)
	US 1998-70440P	19980105 (60)
	US 1998-74086P	19980209 (60)
	US 1998-74092P	19980209 (60)
	US 1998-75945P	19980225 (60)
	US 1998-112850P	19981216 (60)
	US 1997-67411P	19971203 (60)
	US 1997-69278P	19971211 (60)
	US 1997-69334P	19971211 (60)
	US 1997-69335P	19971211 (60)
	US 1997-69425P	19971212 (60)
	US 1997-69694P	19971216 (60)
	US 1997-69696P	19971216 (60)
	US 1997-69702P	19971216 (60)
	US 1997-69870P	19971217 (60)
	US 1997-69873P	19971217 (60)
	US 1997-68017P	19971218 (60)
	US 1998-70440P	19980105 (60)
	US 1998-74086P	19980209 (60)
	US 1998-74092P	19980209 (60)
	US 1998-75945P	19980225 (60)
	US 1998-88742P	19980610 (60)
	US 1998-86414P	19980522 (60)
	US 1998-70440P	19980105 (60)
	US 1998-109304P	19981120 (60)
	US 1998-83500P	19980429 (60)
	US 1998-107783P	19981110 (60)
	US 1998-113296P	19981222 (60)
	US 1999-146222P	19990728 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	9335	
INCL	INCLM: 435/069.700	
	INCLS: 514/012.000; 530/350.000	
NCL	NCLM: 435/069.700	
	NCLS: 514/012.000; 530/350.000	
IC	[7]	
	ICM: A61K038-17	

ICS: C07K014-705; C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l10 and (disassociation constant)
L13 1 L10 AND (DISASSOCIATION CONSTANT)

=> d l13 1 ibib abs

L13 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 2003:311844 USPATFULL
TITLE: Recombinant anti-**interleukin-9**
antibodies

INVENTOR(S): Reed, Jennifer Lynne, Clarksburg, MD, UNITED STATES
Dall'Acqua, William, Gaithersburg, MD, UNITED STATES
Van Snick, Jacques, Wezembeek-Oppem, BELGIUM
Renauld, Jean-Christophe, Kraainem, BELGIUM
Cormont, Francoise, Rixensart, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219439	A1	20031127
APPLICATION INFO.:	US 2003-412703	A1	20030411 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-371728P	20020412 (60)
	US 2002-371683P	20020412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MEDIMMUNE, INC., 35 WEST WATKINS MILL ROAD,
GAITHERSBURG, MD, 20878

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 5807

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The application describes neutralizing chimeric and humanized anti-human IL-9 **antibodies**, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant **antibodies** derived from three murine anti-human IL-9 **antibodies** identified infra as MH9A3, MH9D1, and MH9L1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.